On Friday, the FDA ruled that cancer drug Avastin should not be used to treat breast cancer because Avastin’s risky side-effects outweigh its benefits for breast cancer patients. “Women who take Avastin for metastatic breast cancer risk potentially life threatening or serious side-effects, such as heart attacks or heart failure, severe high blood pressure, bleeding or hemorrhaging,” FDA Commissioner Dr. Margaret Hamburg said. Avastin still has FDA approval for treating lung, kidney, and colon cancer, and despite the ruling, Medicare will still cover Avastin for breast cancer patients. Joe Nocera, op-ed columnist for The New York Times, argues that the FDA made the right decision.
The World is an independent newsroom. We’re not funded by billionaires; instead, we rely on readers and listeners like you. As a listener, you’re a crucial part of our team and our global community. Your support is vital to running our nonprofit newsroom, and we can’t do this work without you. Will you support The World with a gift today? Donations made between now and Dec. 31 will be matched 1:1. Thanks for investing in our work!